Rheumatoid arthritis (RA) is a common inflammatory disease with several implications on health, disability and economy. Conventional treatment for RA centers on anti-inflammatory drugs and specific targeting of tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6). Baricitinib is a novel, Food and Drug Administration (FDA) approved, once daily oral drug that is effective in combination with current treatment and results in significantly reduced symptoms with good safety profile. Further studies are required to find rare side effects and evaluate the long term efficacy in disease modulation and patient symptom reduction. This is a comprehensive review of the literature on baricitinib for the treatment of RA. This review provides an update on the pathophysiology, diagnosis and conventional treatment of RA, then proceeds to introduce baricitinib and the data that exists to support or refute its use in RA. The presented study also indicated clinical trials confirming the effectiveness of baricitinib in this indication.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792534 | PMC |
| http://dx.doi.org/10.5114/reum.2020.102006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dual Relief: How Atopic Dermatitis Treatments Affect Alopecia Areata-A Small Retrospective Cohort Study.
Diagnostics (Basel)
February 2025
Discipline of Dermatology, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Str., 700115 Iasi, Romania.
Atopic dermatitis (AD) and alopecia areata (AA) frequently coexist due to shared immune-mediated mechanisms. Treatments targeting AD, including Janus kinase (JAK) inhibitors and dupilumab, may impact AA outcomes in unpredictable ways. This study aims to evaluate the effects of advanced therapies on patients with concurrent AD and AA to inform treatment strategies.
View Article and Find Full Text PDFExploring new horizons in allergic contact dermatitis treatment: the role of emerging therapies.
Actas Dermosifiliogr
March 2025
Contact Eczema and Immunoallergic Diseases Department. Dermatology, Spain; Dermatology Department. Hospital Universitario San Cecilio, Granada. Spain; Instituto de Investigación Biosanitaria ibs, Granada, Spain. Electronic address:
The resistant and recalcitrant nature of severe allergic contact dermatitis (ACD) makes treatment challenging. With advances in the understanding of the cellular and molecular pathogenesis of this dermatosis, new therapeutic options are emerging. In particular, the use of biologic drugs such as dupilumab and small molecule inhibitors, such as JAK inhibitors have gained momentum given the cross-cutting inhibition of multiple cytokine actions.
View Article and Find Full Text PDFThe therapeutic armamentarium that has been made available from the beginning of the emergency phase of the COVID-19 pandemic to date is briefly reviewed, and an overview of the real-world clinical evidence published by the Italian medical and scientific community during the last three years is presented herein. Prior to the introduction of a vaccine for SARS-CoV-2, several treatment options were implemented from the onset given the evidence that a "cytokine storm" was present during infection with SARS-CoV-2. However, with the exception of tocilizumab, baricitinib and perhaps anakinra, most studies with anti-cytokine biological agents in patients with severe COVID-19 did not show any significant clinical improvement or decrease in mortality at day 28.
View Article and Find Full Text PDFNew and future perspectives in Behçet's syndrome.
Arch Rheumatol
December 2024
Department of Internal Medicine, Division of Rheumatology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye.
Behçet's syndrome is a variable vessel vasculitis characterized by a diverse range of clinical manifestations resulting from inflammation involving several organs and systems. While significant progress has been made in understanding the pathogenesis and treatment of Behçet's syndrome, challenges remain in achieving optimal disease control and preventing long-term complications. This review explores recent advances in the management of Behçet's syndrome, with a focus on emerging therapies and future directions.
View Article and Find Full Text PDFLong-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice.
Acta Derm Venereol
March 2025
Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
In recent years, several new systemic agents (biologics and Janus kinase inhibitors [JAKi]) have been registered for the treatment of moderate-to-severe atopic dermatitis (AD). However, comparisons of real-world drug survival data and insights into treatment patterns of these advanced systemics are limited. Data from a prospective observational single-centre registry were collected from 549 adult AD patients (759 treatment courses) receiving biologics (dupilumab, tralokinumab) or JAKi (abrocitinib, baricitinib, upadacitinib) and analysed using Kaplan-Meier survival curves.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!